Global High-Throughput Screening (HTS) Market
Global High-Throughput Screening (HTS) Market

High-Throughput Screening (HTS) Comprehensive Study by Type (Instruments, Consumables, Software, Service), Application (Drug Discovery, Biochemical Screening, Research, Others), Technology (Cell-Based Assays, Lab-on-a-Chip Technology (LOC), 3D Cell Cultures, Ultra-High Throughput Screening, Others (Perfusion Cell Culture, Label-Free Technology)), End User (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Contract Research Organizations (CROs)) Players and Region - Global Market Outlook to 2026

High-Throughput Screening (HTS) Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Mar 2021 Edition 247 Pages 216 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
What is High-Throughput Screening (HTS) Market?

The high-throughput screening method is used for scientific experimentation in drug discovery and in the fields of biology and chemistry. It allows a researcher to quickly conduct millions of chemical, genetic, or pharmacological tests, using data processing software, liquid handling devices, robotics, and sensitive detectors. The results of these experiments provide starting points for drug design and for understanding the noninteraction or role of a particular location.

The market study is being classified by Type (Instruments, Consumables, Software and Service), by Application (Drug Discovery, Biochemical Screening, Research and Others) and major geographies with country level break-up.

Thermo Fisher Scientific, Inc. (United States), Agilent Technologies, Inc. (United States), Danaher Corporation (United States), PerkinElmer, Inc. (United States), Promega Corporation (United States), Bio-Rad Laboratories, Inc. (United States), Promega Corporation (United States), Hamilton Company (United States), Corning Incorporated (United States) and Charles River Laboratories (United States) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Creative Biolabs (United States), BPS Bioscience, Inc. (United States), Albany Molecular Research Inc. (United States), Tecan Group Ltd. (Switzerland) and Merck KGaA (Germany).

The United States High-Throughput Screening (HTS) market is very fragmented due to the presence of major players. Moreover, major companies in the market are involved in strategic acquisitions, collaborations, and mergers to sustain their position in the market. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global High-Throughput Screening (HTS) market throughout the predicted period.

Segment Analysis
Analyst at AMA have segmented the market study of Global High-Throughput Screening (HTS) market by Type, Application and Region.

On the basis of geography, the market of High-Throughput Screening (HTS) has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • Rising Number of Drug Targets for Screening, And Growing Adoption of Open Innovation Models in Pharmaceutical & Biotechnology Companies
  • Growing Investments by Government and Research Institutes
  • Rising Prevalence of Diseases among People


Restraints
  • Complexities in Assay Development and Capital-Intensive Nature of HTS Instruments

Opportunities
  • Technological Advancements and Increasing Pharmaceutical R&D Expenditure
  • Growing Applications in Stem Cell Research

Challenges
  • Lack of Skilled Professional to Operate the Software’s and Instruments


Market Leaders and some development strategies
In 2020, Danaher Corporation has acquired the biopharma business of General Electric Company to expand its presence in the high-throughput screening market. and In 2019, Agilent Technologies, Inc. has acquired BioTek Instruments to expand its presence and expertise in cell analysis. This development also strengthened the firm’s position in the expansive immune-oncology and immunotherapy areas.



Key Target Audience
High-Throughput Screening (HTS) Service Providers, Software Developers/Vendors, Healthcare and Research Institutes, Pharmaceutical Companies, End-Use Industries and Others

Customization in the Report Available:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase
Report Objectives / Segmentation Covered
By Type
  • Instruments
  • Consumables
  • Software
  • Service
By Application
  • Drug Discovery
  • Biochemical Screening
  • Research
  • Others
By Technology
  • Cell-Based Assays
  • Lab-on-a-Chip Technology (LOC)
  • 3D Cell Cultures
  • Ultra-High Throughput Screening
  • Others (Perfusion Cell Culture, Label-Free Technology)

By End User
  • Pharmaceutical & Biotechnology Companies
  • Academic & Research Institutes
  • Contract Research Organizations (CROs)

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Number of Drug Targets for Screening, And Growing Adoption of Open Innovation Models in Pharmaceutical & Biotechnology Companies
      • 3.2.2. Growing Investments by Government and Research Institutes
      • 3.2.3. Rising Prevalence of Diseases among People
    • 3.3. Market Challenges
      • 3.3.1. Lack of Skilled Professional to Operate the Software’s and Instruments
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global High-Throughput Screening (HTS), by Type, Application, Technology, End User and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global High-Throughput Screening (HTS) (Value)
      • 5.2.1. Global High-Throughput Screening (HTS) by: Type (Value)
        • 5.2.1.1. Instruments
        • 5.2.1.2. Consumables
        • 5.2.1.3. Software
        • 5.2.1.4. Service
      • 5.2.2. Global High-Throughput Screening (HTS) by: Application (Value)
        • 5.2.2.1. Drug Discovery
        • 5.2.2.2. Biochemical Screening
        • 5.2.2.3. Research
        • 5.2.2.4. Others
      • 5.2.3. Global High-Throughput Screening (HTS) by: Technology (Value)
        • 5.2.3.1. Cell-Based Assays
        • 5.2.3.2. Lab-on-a-Chip Technology (LOC)
        • 5.2.3.3. 3D Cell Cultures
        • 5.2.3.4. Ultra-High Throughput Screening
        • 5.2.3.5. Others (Perfusion Cell Culture, Label-Free Technology)
      • 5.2.4. Global High-Throughput Screening (HTS) by: End User (Value)
        • 5.2.4.1. Pharmaceutical & Biotechnology Companies
        • 5.2.4.2. Academic & Research Institutes
        • 5.2.4.3. Contract Research Organizations (CROs)
      • 5.2.5. Global High-Throughput Screening (HTS) Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. High-Throughput Screening (HTS): Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Thermo Fisher Scientific, Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Agilent Technologies, Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Danaher Corporation (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. PerkinElmer, Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Promega Corporation (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Bio-Rad Laboratories, Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Promega Corporation (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Hamilton Company (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Corning Incorporated (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Charles River Laboratories (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global High-Throughput Screening (HTS) Sale, by Type, Application, Technology, End User and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global High-Throughput Screening (HTS) (Value)
      • 7.2.1. Global High-Throughput Screening (HTS) by: Type (Value)
        • 7.2.1.1. Instruments
        • 7.2.1.2. Consumables
        • 7.2.1.3. Software
        • 7.2.1.4. Service
      • 7.2.2. Global High-Throughput Screening (HTS) by: Application (Value)
        • 7.2.2.1. Drug Discovery
        • 7.2.2.2. Biochemical Screening
        • 7.2.2.3. Research
        • 7.2.2.4. Others
      • 7.2.3. Global High-Throughput Screening (HTS) by: Technology (Value)
        • 7.2.3.1. Cell-Based Assays
        • 7.2.3.2. Lab-on-a-Chip Technology (LOC)
        • 7.2.3.3. 3D Cell Cultures
        • 7.2.3.4. Ultra-High Throughput Screening
        • 7.2.3.5. Others (Perfusion Cell Culture, Label-Free Technology)
      • 7.2.4. Global High-Throughput Screening (HTS) by: End User (Value)
        • 7.2.4.1. Pharmaceutical & Biotechnology Companies
        • 7.2.4.2. Academic & Research Institutes
        • 7.2.4.3. Contract Research Organizations (CROs)
      • 7.2.5. Global High-Throughput Screening (HTS) Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. High-Throughput Screening (HTS): by Type(USD Million)
  • Table 2. High-Throughput Screening (HTS) Instruments , by Region USD Million (2015-2020)
  • Table 3. High-Throughput Screening (HTS) Consumables , by Region USD Million (2015-2020)
  • Table 4. High-Throughput Screening (HTS) Software , by Region USD Million (2015-2020)
  • Table 5. High-Throughput Screening (HTS) Service , by Region USD Million (2015-2020)
  • Table 6. High-Throughput Screening (HTS): by Application(USD Million)
  • Table 7. High-Throughput Screening (HTS) Drug Discovery , by Region USD Million (2015-2020)
  • Table 8. High-Throughput Screening (HTS) Biochemical Screening , by Region USD Million (2015-2020)
  • Table 9. High-Throughput Screening (HTS) Research , by Region USD Million (2015-2020)
  • Table 10. High-Throughput Screening (HTS) Others , by Region USD Million (2015-2020)
  • Table 11. High-Throughput Screening (HTS): by Technology(USD Million)
  • Table 12. High-Throughput Screening (HTS) Cell-Based Assays , by Region USD Million (2015-2020)
  • Table 13. High-Throughput Screening (HTS) Lab-on-a-Chip Technology (LOC) , by Region USD Million (2015-2020)
  • Table 14. High-Throughput Screening (HTS) 3D Cell Cultures , by Region USD Million (2015-2020)
  • Table 15. High-Throughput Screening (HTS) Ultra-High Throughput Screening , by Region USD Million (2015-2020)
  • Table 16. High-Throughput Screening (HTS) Others (Perfusion Cell Culture, Label-Free Technology) , by Region USD Million (2015-2020)
  • Table 17. High-Throughput Screening (HTS): by End User(USD Million)
  • Table 18. High-Throughput Screening (HTS) Pharmaceutical & Biotechnology Companies , by Region USD Million (2015-2020)
  • Table 19. High-Throughput Screening (HTS) Academic & Research Institutes , by Region USD Million (2015-2020)
  • Table 20. High-Throughput Screening (HTS) Contract Research Organizations (CROs) , by Region USD Million (2015-2020)
  • Table 21. South America High-Throughput Screening (HTS), by Country USD Million (2015-2020)
  • Table 22. South America High-Throughput Screening (HTS), by Type USD Million (2015-2020)
  • Table 23. South America High-Throughput Screening (HTS), by Application USD Million (2015-2020)
  • Table 24. South America High-Throughput Screening (HTS), by Technology USD Million (2015-2020)
  • Table 25. South America High-Throughput Screening (HTS), by End User USD Million (2015-2020)
  • Table 26. Brazil High-Throughput Screening (HTS), by Type USD Million (2015-2020)
  • Table 27. Brazil High-Throughput Screening (HTS), by Application USD Million (2015-2020)
  • Table 28. Brazil High-Throughput Screening (HTS), by Technology USD Million (2015-2020)
  • Table 29. Brazil High-Throughput Screening (HTS), by End User USD Million (2015-2020)
  • Table 30. Argentina High-Throughput Screening (HTS), by Type USD Million (2015-2020)
  • Table 31. Argentina High-Throughput Screening (HTS), by Application USD Million (2015-2020)
  • Table 32. Argentina High-Throughput Screening (HTS), by Technology USD Million (2015-2020)
  • Table 33. Argentina High-Throughput Screening (HTS), by End User USD Million (2015-2020)
  • Table 34. Rest of South America High-Throughput Screening (HTS), by Type USD Million (2015-2020)
  • Table 35. Rest of South America High-Throughput Screening (HTS), by Application USD Million (2015-2020)
  • Table 36. Rest of South America High-Throughput Screening (HTS), by Technology USD Million (2015-2020)
  • Table 37. Rest of South America High-Throughput Screening (HTS), by End User USD Million (2015-2020)
  • Table 38. Asia Pacific High-Throughput Screening (HTS), by Country USD Million (2015-2020)
  • Table 39. Asia Pacific High-Throughput Screening (HTS), by Type USD Million (2015-2020)
  • Table 40. Asia Pacific High-Throughput Screening (HTS), by Application USD Million (2015-2020)
  • Table 41. Asia Pacific High-Throughput Screening (HTS), by Technology USD Million (2015-2020)
  • Table 42. Asia Pacific High-Throughput Screening (HTS), by End User USD Million (2015-2020)
  • Table 43. China High-Throughput Screening (HTS), by Type USD Million (2015-2020)
  • Table 44. China High-Throughput Screening (HTS), by Application USD Million (2015-2020)
  • Table 45. China High-Throughput Screening (HTS), by Technology USD Million (2015-2020)
  • Table 46. China High-Throughput Screening (HTS), by End User USD Million (2015-2020)
  • Table 47. Japan High-Throughput Screening (HTS), by Type USD Million (2015-2020)
  • Table 48. Japan High-Throughput Screening (HTS), by Application USD Million (2015-2020)
  • Table 49. Japan High-Throughput Screening (HTS), by Technology USD Million (2015-2020)
  • Table 50. Japan High-Throughput Screening (HTS), by End User USD Million (2015-2020)
  • Table 51. India High-Throughput Screening (HTS), by Type USD Million (2015-2020)
  • Table 52. India High-Throughput Screening (HTS), by Application USD Million (2015-2020)
  • Table 53. India High-Throughput Screening (HTS), by Technology USD Million (2015-2020)
  • Table 54. India High-Throughput Screening (HTS), by End User USD Million (2015-2020)
  • Table 55. South Korea High-Throughput Screening (HTS), by Type USD Million (2015-2020)
  • Table 56. South Korea High-Throughput Screening (HTS), by Application USD Million (2015-2020)
  • Table 57. South Korea High-Throughput Screening (HTS), by Technology USD Million (2015-2020)
  • Table 58. South Korea High-Throughput Screening (HTS), by End User USD Million (2015-2020)
  • Table 59. Taiwan High-Throughput Screening (HTS), by Type USD Million (2015-2020)
  • Table 60. Taiwan High-Throughput Screening (HTS), by Application USD Million (2015-2020)
  • Table 61. Taiwan High-Throughput Screening (HTS), by Technology USD Million (2015-2020)
  • Table 62. Taiwan High-Throughput Screening (HTS), by End User USD Million (2015-2020)
  • Table 63. Australia High-Throughput Screening (HTS), by Type USD Million (2015-2020)
  • Table 64. Australia High-Throughput Screening (HTS), by Application USD Million (2015-2020)
  • Table 65. Australia High-Throughput Screening (HTS), by Technology USD Million (2015-2020)
  • Table 66. Australia High-Throughput Screening (HTS), by End User USD Million (2015-2020)
  • Table 67. Rest of Asia-Pacific High-Throughput Screening (HTS), by Type USD Million (2015-2020)
  • Table 68. Rest of Asia-Pacific High-Throughput Screening (HTS), by Application USD Million (2015-2020)
  • Table 69. Rest of Asia-Pacific High-Throughput Screening (HTS), by Technology USD Million (2015-2020)
  • Table 70. Rest of Asia-Pacific High-Throughput Screening (HTS), by End User USD Million (2015-2020)
  • Table 71. Europe High-Throughput Screening (HTS), by Country USD Million (2015-2020)
  • Table 72. Europe High-Throughput Screening (HTS), by Type USD Million (2015-2020)
  • Table 73. Europe High-Throughput Screening (HTS), by Application USD Million (2015-2020)
  • Table 74. Europe High-Throughput Screening (HTS), by Technology USD Million (2015-2020)
  • Table 75. Europe High-Throughput Screening (HTS), by End User USD Million (2015-2020)
  • Table 76. Germany High-Throughput Screening (HTS), by Type USD Million (2015-2020)
  • Table 77. Germany High-Throughput Screening (HTS), by Application USD Million (2015-2020)
  • Table 78. Germany High-Throughput Screening (HTS), by Technology USD Million (2015-2020)
  • Table 79. Germany High-Throughput Screening (HTS), by End User USD Million (2015-2020)
  • Table 80. France High-Throughput Screening (HTS), by Type USD Million (2015-2020)
  • Table 81. France High-Throughput Screening (HTS), by Application USD Million (2015-2020)
  • Table 82. France High-Throughput Screening (HTS), by Technology USD Million (2015-2020)
  • Table 83. France High-Throughput Screening (HTS), by End User USD Million (2015-2020)
  • Table 84. Italy High-Throughput Screening (HTS), by Type USD Million (2015-2020)
  • Table 85. Italy High-Throughput Screening (HTS), by Application USD Million (2015-2020)
  • Table 86. Italy High-Throughput Screening (HTS), by Technology USD Million (2015-2020)
  • Table 87. Italy High-Throughput Screening (HTS), by End User USD Million (2015-2020)
  • Table 88. United Kingdom High-Throughput Screening (HTS), by Type USD Million (2015-2020)
  • Table 89. United Kingdom High-Throughput Screening (HTS), by Application USD Million (2015-2020)
  • Table 90. United Kingdom High-Throughput Screening (HTS), by Technology USD Million (2015-2020)
  • Table 91. United Kingdom High-Throughput Screening (HTS), by End User USD Million (2015-2020)
  • Table 92. Netherlands High-Throughput Screening (HTS), by Type USD Million (2015-2020)
  • Table 93. Netherlands High-Throughput Screening (HTS), by Application USD Million (2015-2020)
  • Table 94. Netherlands High-Throughput Screening (HTS), by Technology USD Million (2015-2020)
  • Table 95. Netherlands High-Throughput Screening (HTS), by End User USD Million (2015-2020)
  • Table 96. Rest of Europe High-Throughput Screening (HTS), by Type USD Million (2015-2020)
  • Table 97. Rest of Europe High-Throughput Screening (HTS), by Application USD Million (2015-2020)
  • Table 98. Rest of Europe High-Throughput Screening (HTS), by Technology USD Million (2015-2020)
  • Table 99. Rest of Europe High-Throughput Screening (HTS), by End User USD Million (2015-2020)
  • Table 100. MEA High-Throughput Screening (HTS), by Country USD Million (2015-2020)
  • Table 101. MEA High-Throughput Screening (HTS), by Type USD Million (2015-2020)
  • Table 102. MEA High-Throughput Screening (HTS), by Application USD Million (2015-2020)
  • Table 103. MEA High-Throughput Screening (HTS), by Technology USD Million (2015-2020)
  • Table 104. MEA High-Throughput Screening (HTS), by End User USD Million (2015-2020)
  • Table 105. Middle East High-Throughput Screening (HTS), by Type USD Million (2015-2020)
  • Table 106. Middle East High-Throughput Screening (HTS), by Application USD Million (2015-2020)
  • Table 107. Middle East High-Throughput Screening (HTS), by Technology USD Million (2015-2020)
  • Table 108. Middle East High-Throughput Screening (HTS), by End User USD Million (2015-2020)
  • Table 109. Africa High-Throughput Screening (HTS), by Type USD Million (2015-2020)
  • Table 110. Africa High-Throughput Screening (HTS), by Application USD Million (2015-2020)
  • Table 111. Africa High-Throughput Screening (HTS), by Technology USD Million (2015-2020)
  • Table 112. Africa High-Throughput Screening (HTS), by End User USD Million (2015-2020)
  • Table 113. North America High-Throughput Screening (HTS), by Country USD Million (2015-2020)
  • Table 114. North America High-Throughput Screening (HTS), by Type USD Million (2015-2020)
  • Table 115. North America High-Throughput Screening (HTS), by Application USD Million (2015-2020)
  • Table 116. North America High-Throughput Screening (HTS), by Technology USD Million (2015-2020)
  • Table 117. North America High-Throughput Screening (HTS), by End User USD Million (2015-2020)
  • Table 118. United States High-Throughput Screening (HTS), by Type USD Million (2015-2020)
  • Table 119. United States High-Throughput Screening (HTS), by Application USD Million (2015-2020)
  • Table 120. United States High-Throughput Screening (HTS), by Technology USD Million (2015-2020)
  • Table 121. United States High-Throughput Screening (HTS), by End User USD Million (2015-2020)
  • Table 122. Canada High-Throughput Screening (HTS), by Type USD Million (2015-2020)
  • Table 123. Canada High-Throughput Screening (HTS), by Application USD Million (2015-2020)
  • Table 124. Canada High-Throughput Screening (HTS), by Technology USD Million (2015-2020)
  • Table 125. Canada High-Throughput Screening (HTS), by End User USD Million (2015-2020)
  • Table 126. Mexico High-Throughput Screening (HTS), by Type USD Million (2015-2020)
  • Table 127. Mexico High-Throughput Screening (HTS), by Application USD Million (2015-2020)
  • Table 128. Mexico High-Throughput Screening (HTS), by Technology USD Million (2015-2020)
  • Table 129. Mexico High-Throughput Screening (HTS), by End User USD Million (2015-2020)
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. High-Throughput Screening (HTS): by Type(USD Million)
  • Table 141. High-Throughput Screening (HTS) Instruments , by Region USD Million (2021-2026)
  • Table 142. High-Throughput Screening (HTS) Consumables , by Region USD Million (2021-2026)
  • Table 143. High-Throughput Screening (HTS) Software , by Region USD Million (2021-2026)
  • Table 144. High-Throughput Screening (HTS) Service , by Region USD Million (2021-2026)
  • Table 145. High-Throughput Screening (HTS): by Application(USD Million)
  • Table 146. High-Throughput Screening (HTS) Drug Discovery , by Region USD Million (2021-2026)
  • Table 147. High-Throughput Screening (HTS) Biochemical Screening , by Region USD Million (2021-2026)
  • Table 148. High-Throughput Screening (HTS) Research , by Region USD Million (2021-2026)
  • Table 149. High-Throughput Screening (HTS) Others , by Region USD Million (2021-2026)
  • Table 150. High-Throughput Screening (HTS): by Technology(USD Million)
  • Table 151. High-Throughput Screening (HTS) Cell-Based Assays , by Region USD Million (2021-2026)
  • Table 152. High-Throughput Screening (HTS) Lab-on-a-Chip Technology (LOC) , by Region USD Million (2021-2026)
  • Table 153. High-Throughput Screening (HTS) 3D Cell Cultures , by Region USD Million (2021-2026)
  • Table 154. High-Throughput Screening (HTS) Ultra-High Throughput Screening , by Region USD Million (2021-2026)
  • Table 155. High-Throughput Screening (HTS) Others (Perfusion Cell Culture, Label-Free Technology) , by Region USD Million (2021-2026)
  • Table 156. High-Throughput Screening (HTS): by End User(USD Million)
  • Table 157. High-Throughput Screening (HTS) Pharmaceutical & Biotechnology Companies , by Region USD Million (2021-2026)
  • Table 158. High-Throughput Screening (HTS) Academic & Research Institutes , by Region USD Million (2021-2026)
  • Table 159. High-Throughput Screening (HTS) Contract Research Organizations (CROs) , by Region USD Million (2021-2026)
  • Table 160. South America High-Throughput Screening (HTS), by Country USD Million (2021-2026)
  • Table 161. South America High-Throughput Screening (HTS), by Type USD Million (2021-2026)
  • Table 162. South America High-Throughput Screening (HTS), by Application USD Million (2021-2026)
  • Table 163. South America High-Throughput Screening (HTS), by Technology USD Million (2021-2026)
  • Table 164. South America High-Throughput Screening (HTS), by End User USD Million (2021-2026)
  • Table 165. Brazil High-Throughput Screening (HTS), by Type USD Million (2021-2026)
  • Table 166. Brazil High-Throughput Screening (HTS), by Application USD Million (2021-2026)
  • Table 167. Brazil High-Throughput Screening (HTS), by Technology USD Million (2021-2026)
  • Table 168. Brazil High-Throughput Screening (HTS), by End User USD Million (2021-2026)
  • Table 169. Argentina High-Throughput Screening (HTS), by Type USD Million (2021-2026)
  • Table 170. Argentina High-Throughput Screening (HTS), by Application USD Million (2021-2026)
  • Table 171. Argentina High-Throughput Screening (HTS), by Technology USD Million (2021-2026)
  • Table 172. Argentina High-Throughput Screening (HTS), by End User USD Million (2021-2026)
  • Table 173. Rest of South America High-Throughput Screening (HTS), by Type USD Million (2021-2026)
  • Table 174. Rest of South America High-Throughput Screening (HTS), by Application USD Million (2021-2026)
  • Table 175. Rest of South America High-Throughput Screening (HTS), by Technology USD Million (2021-2026)
  • Table 176. Rest of South America High-Throughput Screening (HTS), by End User USD Million (2021-2026)
  • Table 177. Asia Pacific High-Throughput Screening (HTS), by Country USD Million (2021-2026)
  • Table 178. Asia Pacific High-Throughput Screening (HTS), by Type USD Million (2021-2026)
  • Table 179. Asia Pacific High-Throughput Screening (HTS), by Application USD Million (2021-2026)
  • Table 180. Asia Pacific High-Throughput Screening (HTS), by Technology USD Million (2021-2026)
  • Table 181. Asia Pacific High-Throughput Screening (HTS), by End User USD Million (2021-2026)
  • Table 182. China High-Throughput Screening (HTS), by Type USD Million (2021-2026)
  • Table 183. China High-Throughput Screening (HTS), by Application USD Million (2021-2026)
  • Table 184. China High-Throughput Screening (HTS), by Technology USD Million (2021-2026)
  • Table 185. China High-Throughput Screening (HTS), by End User USD Million (2021-2026)
  • Table 186. Japan High-Throughput Screening (HTS), by Type USD Million (2021-2026)
  • Table 187. Japan High-Throughput Screening (HTS), by Application USD Million (2021-2026)
  • Table 188. Japan High-Throughput Screening (HTS), by Technology USD Million (2021-2026)
  • Table 189. Japan High-Throughput Screening (HTS), by End User USD Million (2021-2026)
  • Table 190. India High-Throughput Screening (HTS), by Type USD Million (2021-2026)
  • Table 191. India High-Throughput Screening (HTS), by Application USD Million (2021-2026)
  • Table 192. India High-Throughput Screening (HTS), by Technology USD Million (2021-2026)
  • Table 193. India High-Throughput Screening (HTS), by End User USD Million (2021-2026)
  • Table 194. South Korea High-Throughput Screening (HTS), by Type USD Million (2021-2026)
  • Table 195. South Korea High-Throughput Screening (HTS), by Application USD Million (2021-2026)
  • Table 196. South Korea High-Throughput Screening (HTS), by Technology USD Million (2021-2026)
  • Table 197. South Korea High-Throughput Screening (HTS), by End User USD Million (2021-2026)
  • Table 198. Taiwan High-Throughput Screening (HTS), by Type USD Million (2021-2026)
  • Table 199. Taiwan High-Throughput Screening (HTS), by Application USD Million (2021-2026)
  • Table 200. Taiwan High-Throughput Screening (HTS), by Technology USD Million (2021-2026)
  • Table 201. Taiwan High-Throughput Screening (HTS), by End User USD Million (2021-2026)
  • Table 202. Australia High-Throughput Screening (HTS), by Type USD Million (2021-2026)
  • Table 203. Australia High-Throughput Screening (HTS), by Application USD Million (2021-2026)
  • Table 204. Australia High-Throughput Screening (HTS), by Technology USD Million (2021-2026)
  • Table 205. Australia High-Throughput Screening (HTS), by End User USD Million (2021-2026)
  • Table 206. Rest of Asia-Pacific High-Throughput Screening (HTS), by Type USD Million (2021-2026)
  • Table 207. Rest of Asia-Pacific High-Throughput Screening (HTS), by Application USD Million (2021-2026)
  • Table 208. Rest of Asia-Pacific High-Throughput Screening (HTS), by Technology USD Million (2021-2026)
  • Table 209. Rest of Asia-Pacific High-Throughput Screening (HTS), by End User USD Million (2021-2026)
  • Table 210. Europe High-Throughput Screening (HTS), by Country USD Million (2021-2026)
  • Table 211. Europe High-Throughput Screening (HTS), by Type USD Million (2021-2026)
  • Table 212. Europe High-Throughput Screening (HTS), by Application USD Million (2021-2026)
  • Table 213. Europe High-Throughput Screening (HTS), by Technology USD Million (2021-2026)
  • Table 214. Europe High-Throughput Screening (HTS), by End User USD Million (2021-2026)
  • Table 215. Germany High-Throughput Screening (HTS), by Type USD Million (2021-2026)
  • Table 216. Germany High-Throughput Screening (HTS), by Application USD Million (2021-2026)
  • Table 217. Germany High-Throughput Screening (HTS), by Technology USD Million (2021-2026)
  • Table 218. Germany High-Throughput Screening (HTS), by End User USD Million (2021-2026)
  • Table 219. France High-Throughput Screening (HTS), by Type USD Million (2021-2026)
  • Table 220. France High-Throughput Screening (HTS), by Application USD Million (2021-2026)
  • Table 221. France High-Throughput Screening (HTS), by Technology USD Million (2021-2026)
  • Table 222. France High-Throughput Screening (HTS), by End User USD Million (2021-2026)
  • Table 223. Italy High-Throughput Screening (HTS), by Type USD Million (2021-2026)
  • Table 224. Italy High-Throughput Screening (HTS), by Application USD Million (2021-2026)
  • Table 225. Italy High-Throughput Screening (HTS), by Technology USD Million (2021-2026)
  • Table 226. Italy High-Throughput Screening (HTS), by End User USD Million (2021-2026)
  • Table 227. United Kingdom High-Throughput Screening (HTS), by Type USD Million (2021-2026)
  • Table 228. United Kingdom High-Throughput Screening (HTS), by Application USD Million (2021-2026)
  • Table 229. United Kingdom High-Throughput Screening (HTS), by Technology USD Million (2021-2026)
  • Table 230. United Kingdom High-Throughput Screening (HTS), by End User USD Million (2021-2026)
  • Table 231. Netherlands High-Throughput Screening (HTS), by Type USD Million (2021-2026)
  • Table 232. Netherlands High-Throughput Screening (HTS), by Application USD Million (2021-2026)
  • Table 233. Netherlands High-Throughput Screening (HTS), by Technology USD Million (2021-2026)
  • Table 234. Netherlands High-Throughput Screening (HTS), by End User USD Million (2021-2026)
  • Table 235. Rest of Europe High-Throughput Screening (HTS), by Type USD Million (2021-2026)
  • Table 236. Rest of Europe High-Throughput Screening (HTS), by Application USD Million (2021-2026)
  • Table 237. Rest of Europe High-Throughput Screening (HTS), by Technology USD Million (2021-2026)
  • Table 238. Rest of Europe High-Throughput Screening (HTS), by End User USD Million (2021-2026)
  • Table 239. MEA High-Throughput Screening (HTS), by Country USD Million (2021-2026)
  • Table 240. MEA High-Throughput Screening (HTS), by Type USD Million (2021-2026)
  • Table 241. MEA High-Throughput Screening (HTS), by Application USD Million (2021-2026)
  • Table 242. MEA High-Throughput Screening (HTS), by Technology USD Million (2021-2026)
  • Table 243. MEA High-Throughput Screening (HTS), by End User USD Million (2021-2026)
  • Table 244. Middle East High-Throughput Screening (HTS), by Type USD Million (2021-2026)
  • Table 245. Middle East High-Throughput Screening (HTS), by Application USD Million (2021-2026)
  • Table 246. Middle East High-Throughput Screening (HTS), by Technology USD Million (2021-2026)
  • Table 247. Middle East High-Throughput Screening (HTS), by End User USD Million (2021-2026)
  • Table 248. Africa High-Throughput Screening (HTS), by Type USD Million (2021-2026)
  • Table 249. Africa High-Throughput Screening (HTS), by Application USD Million (2021-2026)
  • Table 250. Africa High-Throughput Screening (HTS), by Technology USD Million (2021-2026)
  • Table 251. Africa High-Throughput Screening (HTS), by End User USD Million (2021-2026)
  • Table 252. North America High-Throughput Screening (HTS), by Country USD Million (2021-2026)
  • Table 253. North America High-Throughput Screening (HTS), by Type USD Million (2021-2026)
  • Table 254. North America High-Throughput Screening (HTS), by Application USD Million (2021-2026)
  • Table 255. North America High-Throughput Screening (HTS), by Technology USD Million (2021-2026)
  • Table 256. North America High-Throughput Screening (HTS), by End User USD Million (2021-2026)
  • Table 257. United States High-Throughput Screening (HTS), by Type USD Million (2021-2026)
  • Table 258. United States High-Throughput Screening (HTS), by Application USD Million (2021-2026)
  • Table 259. United States High-Throughput Screening (HTS), by Technology USD Million (2021-2026)
  • Table 260. United States High-Throughput Screening (HTS), by End User USD Million (2021-2026)
  • Table 261. Canada High-Throughput Screening (HTS), by Type USD Million (2021-2026)
  • Table 262. Canada High-Throughput Screening (HTS), by Application USD Million (2021-2026)
  • Table 263. Canada High-Throughput Screening (HTS), by Technology USD Million (2021-2026)
  • Table 264. Canada High-Throughput Screening (HTS), by End User USD Million (2021-2026)
  • Table 265. Mexico High-Throughput Screening (HTS), by Type USD Million (2021-2026)
  • Table 266. Mexico High-Throughput Screening (HTS), by Application USD Million (2021-2026)
  • Table 267. Mexico High-Throughput Screening (HTS), by Technology USD Million (2021-2026)
  • Table 268. Mexico High-Throughput Screening (HTS), by End User USD Million (2021-2026)
  • Table 269. Research Programs/Design for This Report
  • Table 270. Key Data Information from Secondary Sources
  • Table 271. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global High-Throughput Screening (HTS): by Type USD Million (2015-2020)
  • Figure 5. Global High-Throughput Screening (HTS): by Application USD Million (2015-2020)
  • Figure 6. Global High-Throughput Screening (HTS): by Technology USD Million (2015-2020)
  • Figure 7. Global High-Throughput Screening (HTS): by End User USD Million (2015-2020)
  • Figure 8. South America High-Throughput Screening (HTS) Share (%), by Country
  • Figure 9. Asia Pacific High-Throughput Screening (HTS) Share (%), by Country
  • Figure 10. Europe High-Throughput Screening (HTS) Share (%), by Country
  • Figure 11. MEA High-Throughput Screening (HTS) Share (%), by Country
  • Figure 12. North America High-Throughput Screening (HTS) Share (%), by Country
  • Figure 13. Global High-Throughput Screening (HTS) share by Players 2020 (%)
  • Figure 14. Global High-Throughput Screening (HTS) share by Players (Top 3) 2020(%)
  • Figure 15. Global High-Throughput Screening (HTS) share by Players (Top 5) 2020(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Thermo Fisher Scientific, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 18. Thermo Fisher Scientific, Inc. (United States) Revenue: by Geography 2020
  • Figure 19. Agilent Technologies, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 20. Agilent Technologies, Inc. (United States) Revenue: by Geography 2020
  • Figure 21. Danaher Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 22. Danaher Corporation (United States) Revenue: by Geography 2020
  • Figure 23. PerkinElmer, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 24. PerkinElmer, Inc. (United States) Revenue: by Geography 2020
  • Figure 25. Promega Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 26. Promega Corporation (United States) Revenue: by Geography 2020
  • Figure 27. Bio-Rad Laboratories, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 28. Bio-Rad Laboratories, Inc. (United States) Revenue: by Geography 2020
  • Figure 29. Promega Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 30. Promega Corporation (United States) Revenue: by Geography 2020
  • Figure 31. Hamilton Company (United States) Revenue, Net Income and Gross profit
  • Figure 32. Hamilton Company (United States) Revenue: by Geography 2020
  • Figure 33. Corning Incorporated (United States) Revenue, Net Income and Gross profit
  • Figure 34. Corning Incorporated (United States) Revenue: by Geography 2020
  • Figure 35. Charles River Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 36. Charles River Laboratories (United States) Revenue: by Geography 2020
  • Figure 37. Global High-Throughput Screening (HTS): by Type USD Million (2021-2026)
  • Figure 38. Global High-Throughput Screening (HTS): by Application USD Million (2021-2026)
  • Figure 39. Global High-Throughput Screening (HTS): by Technology USD Million (2021-2026)
  • Figure 40. Global High-Throughput Screening (HTS): by End User USD Million (2021-2026)
  • Figure 41. South America High-Throughput Screening (HTS) Share (%), by Country
  • Figure 42. Asia Pacific High-Throughput Screening (HTS) Share (%), by Country
  • Figure 43. Europe High-Throughput Screening (HTS) Share (%), by Country
  • Figure 44. MEA High-Throughput Screening (HTS) Share (%), by Country
  • Figure 45. North America High-Throughput Screening (HTS) Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Thermo Fisher Scientific, Inc. (United States)
  • Agilent Technologies, Inc. (United States)
  • Danaher Corporation (United States)
  • PerkinElmer, Inc. (United States)
  • Promega Corporation (United States)
  • Bio-Rad Laboratories, Inc. (United States)
  • Promega Corporation (United States)
  • Hamilton Company (United States)
  • Corning Incorporated (United States)
  • Charles River Laboratories (United States)
Additional players considered in the study are as follows:
Creative Biolabs (United States) , BPS Bioscience, Inc. (United States) , Albany Molecular Research Inc. (United States) , Tecan Group Ltd. (Switzerland) , Merck KGaA (Germany)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation